These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 36064828)

  • 1. A Single-Center Experience with Dupilumab for Atopic or Psoriasiform Dermatitis in Patients with Inflammatory Bowel Disease.
    Spencer EA; Dolinger MT; Dubinsky MC
    Dig Dis Sci; 2023 Apr; 68(4):1121-1124. PubMed ID: 36064828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE).
    Blauvelt A; Guttman-Yassky E; Paller AS; Simpson EL; Cork MJ; Weisman J; Browning J; Soong W; Sun X; Chen Z; Kosloski MP; Kamal MA; Delevry D; Chuang CC; O'Malley JT; Bansal A
    Am J Clin Dermatol; 2022 May; 23(3):365-383. PubMed ID: 35567671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prior Immunogenicity to Anti-TNF Biologics Is Not Associated with Increased Anti-drug Antibodies to Vedolizumab or Ustekinumab.
    Costable NJ; Borman ZA; Ji J; Dubinsky MC; Ungaro RC
    Dig Dis Sci; 2022 Jun; 67(6):2480-2484. PubMed ID: 34021427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.
    Blauvelt A; de Bruin-Weller M; Gooderham M; Cather JC; Weisman J; Pariser D; Simpson EL; Papp KA; Hong HC; Rubel D; Foley P; Prens E; Griffiths CEM; Etoh T; Pinto PH; Pujol RM; Szepietowski JC; Ettler K; Kemény L; Zhu X; Akinlade B; Hultsch T; Mastey V; Gadkari A; Eckert L; Amin N; Graham NMH; Pirozzi G; Stahl N; Yancopoulos GD; Shumel B
    Lancet; 2017 Jun; 389(10086):2287-2303. PubMed ID: 28478972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of infection in elderly patients with inflammatory bowel disease under biologics: A prospective, multicenter, observational, one-year follow-up comparative study.
    Bozon A; Nancey S; Serrero M; Caillo L; Gilletta C; Benezech A; Combes R; Danan G; Akouete S; Pages L; Bourgaux JF; Le Cosquer G; Boivineau L; Meszaros M; Altwegg R
    Clin Res Hepatol Gastroenterol; 2023 May; 47(5):102107. PubMed ID: 36906225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ).
    de Bruin-Weller M; Thaçi D; Smith CH; Reich K; Cork MJ; Radin A; Zhang Q; Akinlade B; Gadkari A; Eckert L; Hultsch T; Chen Z; Pirozzi G; Graham NMH; Shumel B
    Br J Dermatol; 2018 May; 178(5):1083-1101. PubMed ID: 29193016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dupilumab: A review of its use in the treatment of atopic dermatitis.
    Gooderham MJ; Hong HC; Eshtiaghi P; Papp KA
    J Am Acad Dermatol; 2018 Mar; 78(3 Suppl 1):S28-S36. PubMed ID: 29471919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atopic dermatitis induced during anti-TNF-α therapy for inflammatory bowel disease: Potential for Th2 inhibition with dupilumab.
    Pagan AD; Ghalili S; Cices A; Facheris P; Tan K; Ungar B; Guttman-Yassky E
    J Allergy Clin Immunol Pract; 2023 Jul; 11(7):2235-2238.e1. PubMed ID: 37088378
    [No Abstract]   [Full Text] [Related]  

  • 9. Evaluation of adult patients with atopic dermatitis treated with dupilumab: A single-center real-life experience.
    Su Küçük Ö; Güneş B; Taşlidere N; Işik BG; Akaslan TÇ; Özgen FP; Bahali AG
    J Cosmet Dermatol; 2022 Oct; 21(10):4781-4787. PubMed ID: 35038377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice.
    Gisbert JP; Chaparro M
    J Crohns Colitis; 2020 Jun; 14(5):694-709. PubMed ID: 31777929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Laboratory Safety from a Randomized 16-Week Phase III Study of Dupilumab in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis.
    Paller AS; Siegfried EC; Cork MJ; Wollenberg A; Arkwright PD; Gonzalez ME; Lockshin B; Chen Z; Bansal A; Levit NA; Prescilla R
    Paediatr Drugs; 2023 Jan; 25(1):67-77. PubMed ID: 36529811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world experience of dupilumab treatment for atopic dermatitis in adults: a retrospective analysis of patients' records.
    Wang C; Kraus CN; Patel KG; Ganesan AK; Grando SA
    Int J Dermatol; 2020 Feb; 59(2):253-256. PubMed ID: 31286499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination treatment with monoclonal antibodies: Dupilumab and ustekinumab for the treatment of severe atopic dermatitis and Crohn disease.
    Alegre-Bailo A; Sánchez-Gilo A; Gonzalo González I; Vicente Martín FJ
    Australas J Dermatol; 2024 Feb; 65(1):63-66. PubMed ID: 37929636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. No Increased Risk of Overall Infection in Adults with Moderate-to-Severe Atopic Dermatitis Treated for up to 4 Years with Dupilumab.
    Blauvelt A; Wollenberg A; Eichenfield LF; Zhang H; Sierka D; Khokhar FA; Vakil J; Shabbir A; Marco AR; Cyr SL
    Adv Ther; 2023 Jan; 40(1):367-380. PubMed ID: 36318387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.
    Beck LA; Deleuran M; Bissonnette R; de Bruin-Weller M; Galus R; Nakahara T; Seo SJ; Khokhar FA; Vakil J; Xiao J; Marco AR; Levit NA; O'Malley JT; Shabbir A
    Am J Clin Dermatol; 2022 May; 23(3):393-408. PubMed ID: 35503163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psoriasiform dermatitis during dupilumab treatment for moderate-to-severe atopic dermatitis in children.
    Parker JJ; Sugarman JL; Silverberg NB; Gonzalez ME; Ramien ML; Teng JMC; Paller AS
    Pediatr Dermatol; 2021 Nov; 38(6):1500-1505. PubMed ID: 34647354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Report of two sisters with Netherton syndrome successfully treated with dupilumab and review of the literature.
    Martin-García C; Godoy E; Cabrera A; Cañueto J; Muñoz-Bellido FJ; Perez-Pazos J; Dávila I
    Int J Immunopathol Pharmacol; 2023; 37():3946320231172881. PubMed ID: 37200480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission.
    Wang Y; Wang J; Pekow J; Dalal S; Cohen RD; Ollech J; Israel A; Shogan BD; Micic D; Cannon L; Umanskiy K; Hurst R; Hyman N; Rubin DT; Sakuraba A
    J Gastroenterol Hepatol; 2019 Dec; 34(12):2090-2095. PubMed ID: 31169926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dupilumab Improves Clinical Scores in Children and Adolescents With Moderate to Severe Atopic Dermatitis: A Real-World, Single-Center Study.
    Pagan AD; David E; Ungar B; Ghalili S; He H; Guttman-Yassky E
    J Allergy Clin Immunol Pract; 2022 Sep; 10(9):2378-2385. PubMed ID: 35753667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of dupilumab in patients with atopic dermatitis: expert opinion.
    Francuzik W; Alexiou A; Worm M
    Expert Opin Drug Saf; 2021 Sep; 20(9):997-1004. PubMed ID: 34114910
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.